Fujihara-Mino Akiko, Mitamura Yoshinori, Inomoto Naoki, Sano Hiroki, Akaiwa Kei, Semba Kentaro
Department of Ophthalmology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Clin Ophthalmol. 2016 Jul 18;10:1305-13. doi: 10.2147/OPTH.S110793. eCollection 2016.
To determine the optical coherence tomography (OCT) parameters that are predictive of visual outcome after anti-VEGF therapy for a retinal vein occlusion (RVO).
Fifty-seven eyes with macular edema (ME) secondary to a central or branch RVO treated with bevacizumab or ranibizumab were studied. Spectral-domain OCT and microperimetry were performed before, 1, 3, and 6 months after the treatment and at the final visit. Central retinal thickness (CRT), macular volume (MV), integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), and foveal bulge (FB), and photoreceptor outer segment (PROS) length were determined.
The mean follow-up period was 17.8±11.5 months. In 46 of the 57 eyes, a resolution of the ME was achieved. The pretreatment CRT and MV, presence of intact ELM, EZ, and FB, and PROS length at the time of ME resolution were significantly correlated with the best-corrected visual acuity and retinal sensitivity at the final visit (P<0.050). Multiple regression analyses showed that the pretreatment MV had the highest correlation with the posttreatment best-corrected visual acuity and retinal sensitivity (P<0.050).
The CRT, MV, ELM, EZ, FB, and PROS length are predictive factors for the visual outcome after anti-VEGF therapy for RVO.
确定可预测视网膜静脉阻塞(RVO)抗VEGF治疗后视力预后的光学相干断层扫描(OCT)参数。
对57只因中心性或分支性RVO继发黄斑水肿(ME)而接受贝伐单抗或雷珠单抗治疗的眼睛进行研究。在治疗前、治疗后1个月、3个月、6个月以及最后一次随访时进行了光谱域OCT和微视野检查。测定了中心视网膜厚度(CRT)、黄斑体积(MV)、外界膜(ELM)、椭圆体带(EZ)、黄斑隆起(FB)的完整性以及光感受器外节(PROS)长度。
平均随访期为17.8±11.5个月。57只眼中有46只实现了ME的消退。ME消退时的治疗前CRT和MV、完整ELM、EZ和FB的存在以及PROS长度与最后一次随访时的最佳矫正视力和视网膜敏感度显著相关(P<0.050)。多元回归分析显示,治疗前MV与治疗后最佳矫正视力和视网膜敏感度的相关性最高(P<0.050)。
CRT、MV、ELM、EZ、FB和PROS长度是RVO抗VEGF治疗后视力预后的预测因素。